Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis

医学 彭布罗利珠单抗 内科学 外科肿瘤学 肿瘤科 转移性尿路上皮癌 危险系数 荟萃分析 置信区间 转移
作者
Takafumi Yanagisawa,Keiichiro Mori,Satoshi Katayama,Hadi Mostafaei,Fahad Quhal,Ekaterina Laukhtina,Pawel Rajwa,Reza Sari Motlagh,Abdulmajeed Aydh,Frederik König,Nico C. Grossmann,Benjamin Pradere,Jun Miki,Takahiro Kimura,Shin Egawa,Shahrokh F. Shariat
出处
期刊:International Journal of Clinical Oncology [Springer Science+Business Media]
标识
DOI:10.1007/s10147-021-02061-0
摘要

Pembrolizumab is the standard for the first and second lines in treating metastatic urothelial carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of pretreatment clinical characteristics and hematologic biomarkers for prognosticating response to pembrolizumab in patients with metastatic UC. PUBMED®, Web of Science™, and Scopus® databases were searched for articles published before May 2021 according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) statement. Studies were deemed eligible if they evaluated overall survival (OS) in patients with metastatic urothelial carcinoma treated with pembrolizumab and pretreatment clinical characteristics or laboratory examination. Overall, 13 studies comprising 1311 patients were eligible for the meta-analysis. Several pretreatment patients' demographics and hematologic biomarkers were significantly associated with worse OS as follows: Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≥ 2 (Pooled hazard ratio [HR]: 3.24, 95% confidence interval [CI] 2.57-4.09), presence of visceral metastasis (Pooled HR: 1.84, 95% CI 1.42-2.38), presence of liver metastasis (Pooled HR: 4.23, 95% CI 2.18-8.20), higher neutrophil-lymphocyte ratio (NLR) (Pooled HR: 1.29, 95% CI 1.07-1.55) and, higher c-reactive protein (CRP) (Pooled HR: 2.49, 95% CI 1.52-4.07). Metastatic UC patients with poor PS, liver metastasis, higher pretreatment NLR and/or CRP have a worse survival despite pembrolizumab treatment. These findings might help to guide the prognostic tools for clinical decision-making; however, they should be interpreted carefully, owing to limitations regarding the retrospective nature of primary data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
轻松闭月发布了新的文献求助10
1秒前
hong发布了新的文献求助10
2秒前
顾矜应助Richardisme采纳,获得10
2秒前
2秒前
一已仪艺发布了新的文献求助30
2秒前
2秒前
平常的狗应助axn采纳,获得10
2秒前
亿格瑙黛芭鸽哒完成签到,获得积分10
2秒前
Antony发布了新的文献求助10
3秒前
刺猬发布了新的文献求助10
4秒前
mdx完成签到,获得积分10
5秒前
aa发布了新的文献求助30
5秒前
机智完成签到,获得积分10
5秒前
MIDANN完成签到,获得积分10
6秒前
6秒前
巧克力coco完成签到,获得积分10
6秒前
香蕉觅云应助阮楷瑞采纳,获得10
7秒前
7秒前
Hello应助palmer采纳,获得10
7秒前
JamesPei应助如意的代真采纳,获得10
7秒前
平淡晓博发布了新的文献求助10
7秒前
迷路的虔发布了新的文献求助10
7秒前
hong完成签到,获得积分10
8秒前
8秒前
yy关闭了yy文献求助
8秒前
9秒前
领导范儿应助猪猪hero采纳,获得30
9秒前
9秒前
myth完成签到,获得积分10
9秒前
znn发布了新的文献求助10
10秒前
NexusExplorer应助桀桀桀采纳,获得10
10秒前
MIDANN发布了新的文献求助10
10秒前
桐桐应助YY采纳,获得10
10秒前
白白完成签到,获得积分10
11秒前
11秒前
大个应助Antony采纳,获得10
11秒前
11秒前
11秒前
Hello应助帅气的小鸭子采纳,获得10
11秒前
打打应助quw88888采纳,获得10
12秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974602
求助须知:如何正确求助?哪些是违规求助? 3519026
关于积分的说明 11196787
捐赠科研通 3255127
什么是DOI,文献DOI怎么找? 1797693
邀请新用户注册赠送积分活动 877100
科研通“疑难数据库(出版商)”最低求助积分说明 806130